Create Free Account

By creating account you will get access to hot stocks & personalised emails

Race Oncology Ltd

Healthcare AU RAC

1.7AUD
0.01(0.89%)

Last update at 2024-09-16T06:10:00Z

Day Range

1.671.70
LowHigh

52 Week Range

0.642.09
LowHigh

Fundamentals

  • Previous Close 1.69
  • Market Cap282.03M
  • Volume46712
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-14.20338M
  • Revenue TTM4.00M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 1.11M
  • Diluted EPS TTM-0.08

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -9.92342M -11.20198M -6.34032M -3.84597M -3.65940M
Minority interest - - - - -
Net income -9.92342M -11.20198M -6.34032M -3.84597M -3.41355M
Selling general administrative 1.44M 3.78M 2.74M 1.58M 1.21M
Selling and marketing expenses 0.32M 0.18M 0.17M 0.10M 0.56M
Gross profit 1.11M -0.28245M -0.23269M -0.28382M -0.30399M
Reconciled depreciation 0.28M 0.28M 0.28M 0.28M 0.28M
Ebit -13.64964M -11.96370M -6.78405M -4.11172M -3.90526M
Ebitda -13.36845M -11.68250M -6.50286M -3.83053M -3.62406M
Depreciation and amortization 0.28M 0.28M 0.28M 0.28M 0.28M
Non operating income net other - - - - -
Operating income -10.47578M -11.20289M -6.35885M -3.93050M -3.90526M
Other operating expenses -9.59670M -9.98318M -5.50640M -3.12827M 3.91M
Interest expense - 0.05M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.59M 0.05M 0.02M 0.00932M 0.02M
Net interest income 0.59M 0.05M 0.02M 0.00932M 0.02M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.59184M -0.05391M -0.01885M -0.00932M -0.24586M
Total revenue 3.13M 0.71M 0.39M 0.16M 0.02M
Total operating expenses 13.65M 11.96M 6.78M 4.11M 3.91M
Cost of revenue 2.03M 0.99M 0.62M 0.44M 0.53M
Total other income expense net 3.13M 0.71M 0.42M 0.26M 0.25M
Discontinued operations - - - - -
Net income from continuing ops -9.92342M -11.20198M -6.34032M -3.84597M -3.65940M
Net income applicable to common shares -9.92343M -11.20198M -6.34032M -3.84597M -3.65940M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 20.23M 26.64M 37.52M 14.25M 5.93M
Intangible assets - 3.09M 3.37M 3.66M 3.94M
Earning assets - - - - -
Other current assets 0.12M - 0.55M 1.14M -0.00000M
Total liab 1.92M 1.15M 1.42M 0.52M 0.24M
Total stockholder equity 18.31M 25.49M 36.11M 13.72M 5.69M
Deferred long term liab - - - - -
Other current liab 0.67M 0.51M 0.58M 0.21M 0.11M
Common stock 66.95M 61.71M 62.02M 31.50M 19.66M
Capital stock - 61.71M 62.02M 31.50M 19.66M
Retained earnings -57.41816M -43.59882M -33.67540M -22.46644M -15.77056M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 1.39M 21.52M 33.54M 9.32M 1.73M
Cash and equivalents - - - - -
Total current liabilities 1.87M 1.15M 1.42M 0.52M 0.24M
Current deferred revenue - - - - -
Net debt -1.38883M -21.52037M -33.54079M -9.32244M -1.73077M
Short term debt - 0.00000M 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - -18.11033M -28.34141M -9.02898M -3.88945M
Property plant equipment - - - - -
Total current assets 17.42M 23.54M 34.15M 10.59M 2.00M
Long term investments - - - - -
Net tangible assets - 22.39M 32.73M 10.07M 1.75M
Short term investments 15.80M - - - -
Net receivables 0.11M 1.70M 0.06M 0.13M 0.05M
Long term debt - - - - -
Inventory - - - - 0.22M
Accounts payable 1.20M 0.64M 0.83M 0.31M 0.13M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 8.78M 7.38M 7.77M 4.69M 1.80M
Additional paid in capital - - - - -
Common stock total equity - - - - 19.66M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -3.09315M -3.37435M -3.65555M -3.93674M
Deferred long term asset charges - - - - -
Non current assets total 2.81M 3.09M 3.37M 3.66M 3.94M
Capital lease obligations - - - - -
Long term debt total - 0.00000M 0.00000M 0.00000M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments - - - - -
Change to liabilities -0.26554M 0.89M 0.28M 0.05M -0.11759M
Total cashflows from investing activities 0.00000M - - 0.00000M 0.00000M
Net borrowings - - - - -
Total cash from financing activities -1.28255M 30.51M 12.28M 3.21M -0.03384M
Change to operating activities 0.23M 0.59M -1.10546M 0.00042M -0.00351M
Net income -9.92342M -11.20198M -6.34032M -3.84597M -3.41355M
Change in cash -12.02042M 24.22M 7.59M 0.74M -2.72128M
Begin period cash flow 33.54M 9.32M 1.73M 0.99M 3.71M
End period cash flow 21.52M 33.54M 9.32M 1.73M 0.99M
Total cash from operating activities -10.65155M -6.25784M -4.69758M -2.46308M -2.67400M
Issuance of capital stock -1.28255M 30.98M 12.79M 3.34M -
Depreciation 0.28M 0.28M 0.28M 0.28M 0.28M
Other cashflows from investing activities 0.00000M - - 0.00000M 0.00000M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -1.64163M 0.07M -0.07925M -0.04830M -0.00018M
Sale purchase of stock -1.28255M -0.46349M -0.51053M -0.14207M -0.03384M
Other cashflows from financing activities -1.28255M -0.00000M -0.51053M 0.01M -3.34080M
Change to netincome 0.67M 3.11M 2.27M 1.10M 0.83M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.64163M 0.07M -0.07925M -0.04830M -1.91763M
Stock based compensation 0.59M 3.07M 2.28M 1.09M -
Other non cash items -1.00932M 4.66M 1.36M 1.10M 3.38M
Free cash flow -10.65155M -6.25784M -4.69758M -2.46308M -2.67400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RAC
Race Oncology Ltd		 0.01 0.89% 1.70 - - 70.45 15.12 - -21.5133
CSL
CSL Ltd		 -3.57 1.19% 296.69 41.15 31.35 9.60 5.16 10.91 34.93
TLX
Telix Pharmaceuticals Ltd		 -1.23 6.46% 17.82 983.00 21.01 8.47 28.69 8.21 177.65
CU6
Clarity Pharmaceuticals Ltd		 -0.1 1.32% 7.48 - - 204.16 15.91 - -0.7791
NEU
Neuren Pharmaceuticals Ltd		 -0.11 0.80% 13.65 14.32 15.15 9.15 5.27 6.69 8.72

Reports Covered

Stock Research & News

View All

Profile

Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company's lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer activity in solid tumors. The company is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia. In addition, it is investigating the effect of bisantrene on the m6A RNA pathway, following independent research identifying bisantrene as the potent inhibitor of fat mass and obesity-associated protein. The company has collaborations with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. The company was formerly known as Coronado Resources Limited. Race Oncology Limited was incorporated in 2011 and is headquartered in Sydney, Australia.

Race Oncology Ltd

Gateway, 1 Macquarie Place, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Mr. Phillip R. Lynch CEO, MD & Director NA
Dr. Daniel Tillett Chief Scientific Officer & Exec. Director NA
Ms. Christina Manfre Chief Financial Officer NA
Dr. Ajay Duggal Dip Pharm Med, MB ChB, MRCP Interim Chief Medical Officer NA
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD Company Sec. 1963
Dr. Daniel Tillett Chief Executive Officer NA
Dr. Peter M. Smith Ph.D. Executive Director 1963
Prof. Tim Hammond Interim Chief Scientific Officer NA
Dr. Michelle Rashford Chief Medical Officer NA
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. Company Secretary 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.